| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:57 UTC |
|---|
| HMDB ID | HMDB0015341 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Levobunolol |
|---|
| Description | Levobunolol is only found in individuals that have used or taken this drug. It is a nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma. [PubChem]Levobunolol's mechanism of action in reducing IOP is not clearly defined, but is believed to be due to a reduction of the production of aqueous humor via blockage of endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes. |
|---|
| Structure | CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Bunolol | ChEBI | | (S)-5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone | ChEBI | | Levobunololum | ChEBI | | Akorn brand OF levobunolol hydrochloride | HMDB | | Allergan brand OF levobunolol hydrochloride | HMDB | | Apotex brand OF levobunolol hydrochloride | HMDB | | Levobunolol hydrochloride | HMDB | | Novo-levobunolol | HMDB | | Ultracortenol | HMDB | | Vistagan | HMDB | | Ratio levobunolol | HMDB | | Apo-levobunolol | HMDB | | PMS Levobunolol | HMDB | | PMSLevobunolol | HMDB | | Pharm allergan brand OF levobunolol hydrochloride | HMDB | | Pharmascience brand OF levobunolol hydrochloride | HMDB | | AKBeta | HMDB | | Novopharm brand OF levobunolol hydrochloride | HMDB | | Pharm-allergan brand OF levobunolol hydrochloride | HMDB | | Ratiopharm brand OF levobunolol hydrochloride | HMDB | | Ratio-levobunolol | HMDB | | Apo levobunolol | HMDB | | ApoLevobunolol | HMDB | | Betagan | HMDB | | Ciba vision brand OF levobunolol hydrochloride | HMDB | | Novo levobunolol | HMDB | | NovoLevobunolol | HMDB | | PMS-Levobunolol | HMDB |
|
|---|
| Chemical Formula | C17H25NO3 |
|---|
| Average Molecular Weight | 291.3853 |
|---|
| Monoisotopic Molecular Weight | 291.183443671 |
|---|
| IUPAC Name | 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-one |
|---|
| Traditional Name | akβ |
|---|
| CAS Registry Number | 47141-42-4 |
|---|
| SMILES | CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O |
|---|
| InChI Identifier | InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1 |
|---|
| InChI Key | IXHBTMCLRNMKHZ-LBPRGKRZSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Tetralins |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Tetralins |
|---|
| Alternative Parents | |
|---|
| Substituents | - Tetralin
- Aryl alkyl ketone
- Aryl ketone
- Alkyl aryl ether
- 1,2-aminoalcohol
- Ketone
- Secondary alcohol
- Secondary aliphatic amine
- Ether
- Secondary amine
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Alcohol
- Organic nitrogen compound
- Amine
- Organic oxide
- Organic oxygen compound
- Hydrocarbon derivative
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 209 - 211 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.25 g/L | Not Available | | LogP | 2.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.33 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.1867 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.43 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 70.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1704.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 222.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 154.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 165.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 106.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 343.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 384.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 131.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 819.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 396.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1142.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 243.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 281.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 280.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 283.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 15.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Levobunolol,1TMS,isomer #1 | CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C | 2336.5 | Semi standard non polar | 33892256 | | Levobunolol,1TMS,isomer #2 | CC(C)(C)N(C[C@H](O)COC1=CC=CC2=C1CCCC2=O)[Si](C)(C)C | 2513.2 | Semi standard non polar | 33892256 | | Levobunolol,2TMS,isomer #1 | CC(C)(C)N(C[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C)[Si](C)(C)C | 2568.3 | Semi standard non polar | 33892256 | | Levobunolol,2TMS,isomer #1 | CC(C)(C)N(C[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C)[Si](C)(C)C | 2694.0 | Standard non polar | 33892256 | | Levobunolol,2TMS,isomer #1 | CC(C)(C)N(C[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C)[Si](C)(C)C | 2890.1 | Standard polar | 33892256 | | Levobunolol,1TBDMS,isomer #1 | CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C(C)(C)C | 2565.7 | Semi standard non polar | 33892256 | | Levobunolol,1TBDMS,isomer #2 | CC(C)(C)N(C[C@H](O)COC1=CC=CC2=C1CCCC2=O)[Si](C)(C)C(C)(C)C | 2798.8 | Semi standard non polar | 33892256 | | Levobunolol,2TBDMS,isomer #1 | CC(C)(C)N(C[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3054.8 | Semi standard non polar | 33892256 | | Levobunolol,2TBDMS,isomer #1 | CC(C)(C)N(C[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3140.8 | Standard non polar | 33892256 | | Levobunolol,2TBDMS,isomer #1 | CC(C)(C)N(C[C@@H](COC1=CC=CC2=C1CCCC2=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3039.3 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Levobunolol GC-MS (Non-derivatized) - 70eV, Positive | splash10-08gi-9540000000-243680d4a0d98a06ee5e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Levobunolol GC-MS (1 TMS) - 70eV, Positive | splash10-08mu-9423000000-24d9e3e549ee0f3caefc | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Levobunolol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 10V, Positive-QTOF | splash10-0006-1290000000-a27d598a50efb04fd09e | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 20V, Positive-QTOF | splash10-000i-9470000000-fade873eb3e9b9280e3f | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 40V, Positive-QTOF | splash10-0079-9400000000-9c86007a0342c84063d9 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 10V, Negative-QTOF | splash10-01ox-1690000000-01bd12a64aa5a1ac1b0c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 20V, Negative-QTOF | splash10-03di-0900000000-f14eecc41eae40c5ae10 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 40V, Negative-QTOF | splash10-03di-3900000000-bd973c4edbfdfc4ff33c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 10V, Positive-QTOF | splash10-0006-0090000000-528baf592ca874e0be73 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 20V, Positive-QTOF | splash10-022l-3490000000-47baa556e9ab27cc0b6b | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 40V, Positive-QTOF | splash10-0a4i-9400000000-0bc68579194e5bf27651 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 10V, Negative-QTOF | splash10-0006-0290000000-23bba37d597734cfc791 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 20V, Negative-QTOF | splash10-03dl-1910000000-29bcb195f7a66d163c96 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levobunolol 40V, Negative-QTOF | splash10-01oy-0900000000-698fee7bcd270c336dab | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63. [PubMed:2891463 ]
- Gonzalez JP, Clissold SP: Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Dec;34(6):648-61. [PubMed:2892662 ]
- Novack GD: Levobunolol for the long-term treatment of glaucoma. Gen Pharmacol. 1986;17(4):373-7. [PubMed:3019819 ]
- Leung M, Grunwald JE: Short-term effects of topical levobunolol on the human retinal circulation. Eye (Lond). 1997;11 ( Pt 3):371-6. [PubMed:9373479 ]
- Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S: [Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]. Nippon Ganka Gakkai Zasshi. 1999 Jul;103(7):544-50. [PubMed:10443129 ]
- Ishibashi T, Yokoi N, Kinoshita S: Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface. Cornea. 2003 Nov;22(8):709-15. [PubMed:14576520 ]
- Dong Y, Ishikawa H, Wu Y, Yoshitomi T: Vasodilatory mechanism of levobunolol on vascular smooth muscle cells. Exp Eye Res. 2007 Jun;84(6):1039-46. Epub 2007 Jan 27. [PubMed:17459374 ]
|
|---|